Ramtin Pourahmad , Kiarash saleki , Mehrad Zare Gholinejad , Cena Aram , Ali Soltani Farsani , Mohammad Banazadeh , Abbas Tafakhori
{"title":"Exploring the effect of gut microbiome on Alzheimer's disease","authors":"Ramtin Pourahmad , Kiarash saleki , Mehrad Zare Gholinejad , Cena Aram , Ali Soltani Farsani , Mohammad Banazadeh , Abbas Tafakhori","doi":"10.1016/j.bbrep.2024.101776","DOIUrl":null,"url":null,"abstract":"<div><p>Alzheimer's disease (AD) is the most widespread and irreversible form of dementia and accounts for more than half of dementia cases. The most significant risk factors for AD are aging-related exacerbations, degradation of anatomical pathways, environmental variables and mitochondrial dysfunction. Finding a decisive therapeutic solution is a major current issue. Nuanced interactions between major neuropathological mechanisms in AD in patients and microbiome have recently gained rising attention. The presence of bacterial amyloid in the gut triggers the immune system, resulting in increased immune feedbacks and endogenous neuronal amyloid within the CNS. Also, early clinical research revealed that changing the microbiome with beneficial bacteria or probiotics could affect brain function in AD. New approaches focus on the possible neuroprotective action of disease-modifying medications in AD. In the present review, we discuss the impact of the gut microbiota on the brain and review emerging research that suggests a disruption in the microbiota-brain axis can affect AD by mediating neuroinflammation. Such novel methods could help the development of novel therapeutics for AD.</p></div>","PeriodicalId":8771,"journal":{"name":"Biochemistry and Biophysics Reports","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2024-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2405580824001407/pdfft?md5=ffd7e88c285f228951054a3293c2ac40&pid=1-s2.0-S2405580824001407-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biochemistry and Biophysics Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2405580824001407","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Alzheimer's disease (AD) is the most widespread and irreversible form of dementia and accounts for more than half of dementia cases. The most significant risk factors for AD are aging-related exacerbations, degradation of anatomical pathways, environmental variables and mitochondrial dysfunction. Finding a decisive therapeutic solution is a major current issue. Nuanced interactions between major neuropathological mechanisms in AD in patients and microbiome have recently gained rising attention. The presence of bacterial amyloid in the gut triggers the immune system, resulting in increased immune feedbacks and endogenous neuronal amyloid within the CNS. Also, early clinical research revealed that changing the microbiome with beneficial bacteria or probiotics could affect brain function in AD. New approaches focus on the possible neuroprotective action of disease-modifying medications in AD. In the present review, we discuss the impact of the gut microbiota on the brain and review emerging research that suggests a disruption in the microbiota-brain axis can affect AD by mediating neuroinflammation. Such novel methods could help the development of novel therapeutics for AD.
阿尔茨海默病(AD)是痴呆症中最普遍、最不可逆的一种,占痴呆症病例的一半以上。阿尔茨海默病最主要的风险因素是与衰老相关的病情加重、解剖途径退化、环境变量和线粒体功能障碍。找到决定性的治疗方案是当前的主要问题。最近,老年痴呆症患者的主要神经病理机制与微生物组之间微妙的相互作用日益受到关注。肠道中存在的细菌淀粉样蛋白会触发免疫系统,导致中枢神经系统内的免疫反馈和内源性神经元淀粉样蛋白增加。此外,早期的临床研究显示,使用有益菌或益生菌改变微生物组可影响注意力缺失症患者的大脑功能。新的研究方法主要集中在改变病情的药物可能对 AD 起到的神经保护作用上。在本综述中,我们讨论了肠道微生物群对大脑的影响,并回顾了新出现的研究,这些研究表明,微生物群-大脑轴的紊乱可通过介导神经炎症来影响注意力缺失症。这种新方法有助于开发治疗 AD 的新型疗法。
期刊介绍:
Open access, online only, peer-reviewed international journal in the Life Sciences, established in 2014 Biochemistry and Biophysics Reports (BB Reports) publishes original research in all aspects of Biochemistry, Biophysics and related areas like Molecular and Cell Biology. BB Reports welcomes solid though more preliminary, descriptive and small scale results if they have the potential to stimulate and/or contribute to future research, leading to new insights or hypothesis. Primary criteria for acceptance is that the work is original, scientifically and technically sound and provides valuable knowledge to life sciences research. We strongly believe all results deserve to be published and documented for the advancement of science. BB Reports specifically appreciates receiving reports on: Negative results, Replication studies, Reanalysis of previous datasets.